TICKERNOMICS Sign up
Last Update: 2023-12-23 05:59:44
AbCellera Biologics Inc. ( ABCL ) https://www.abcellera.com
5.69USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Canada
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-44.92%
ABCL
SPY
30.72%
-86.85%
ABCL
SPY
112.82%
ABCL
0.00%
SPY
201.04%
ABCL
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1540.12
1007.46
1.27
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-11.93
30.56
1.30
-12.31
0.00
-6.69
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-831.79
100.00
-298.97
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-18.06
-16.99
0.00
Other Earnings and Cash Flow Stats:
AbCellera Biologics Inc. ( ABCL ) Net Income TTM ($MM) is -71.99
AbCellera Biologics Inc. ( ABCL ) Operating Income TTM ($MM) is -114.76
AbCellera Biologics Inc. ( ABCL ) Owners' Earnings Annual ($MM) is 0.00
AbCellera Biologics Inc. ( ABCL ) Current Price to Owners' Earnings ratio is 0.00
AbCellera Biologics Inc. ( ABCL ) EBITDA TTM ($MM) is -59.91
AbCellera Biologics Inc. ( ABCL ) EBITDA Margin is -298.97%
Capital Allocation:
AbCellera Biologics Inc. ( ABCL ) has paid 0.00 dividends per share and bought back 26.321322 million shares in the past 12 months
AbCellera Biologics Inc. ( ABCL ) has increased its debt by 4.649 million USD in the last 12 months
Capital Structure:
AbCellera Biologics Inc. ( ABCL ) Interest-bearing Debt ($MM) as of last quarter is 80
AbCellera Biologics Inc. ( ABCL ) Annual Working Capital Investments ($MM) are 14
AbCellera Biologics Inc. ( ABCL ) Book Value ($MM) as of last quarter is 1182
AbCellera Biologics Inc. ( ABCL ) Debt/Capital as of last quarter is 6%
Other Balance Sheet Stats:
AbCellera Biologics Inc. ( ABCL ) has 172 million in cash on hand as of last quarter
AbCellera Biologics Inc. ( ABCL ) has 110 million of liabilities due within 12 months, and long term debt 0 as of last quarter
AbCellera Biologics Inc. ( ABCL ) has 289 common shares outstanding as of last quarter
AbCellera Biologics Inc. ( ABCL ) has 0 million USD of preferred stock value
Academic Scores:
AbCellera Biologics Inc. ( ABCL ) Altman Z-Score is 3.34 as of last quarter
AbCellera Biologics Inc. ( ABCL ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
AbCellera Biologics Inc. ( ABCL ) largest shareholder is Federated Hermes Inc owning 3254353 shares at 18.52 ($MM) value
Holdings Ltd. Thermopylae(an insider) Bought 153000 shares of AbCellera Biologics Inc. ( ABCL ) for the amount of $997560.00 on 2023-05-26
28.34% of AbCellera Biologics Inc. ( ABCL ) is held by insiders, and 46.99% is held by institutions
AbCellera Biologics Inc. ( ABCL ) went public on 2020-12-11
Other AbCellera Biologics Inc. ( ABCL ) financial metrics:
FCF:-202.76
Unlevered Free Cash Flow:0.00
EPS:-0.40
Operating Margin:-831.79
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-9.68
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About AbCellera Biologics Inc. ( ABCL ) :
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.